Vallentuna, Sweden

Orla McCallion

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Oxthera Intellectual Property. Active years: 2020.

USPTO Granted Patents = 1 


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Orla McCallion: Innovator in Oxalate-Related Disorder Treatments

Introduction

Orla McCallion is a notable inventor based in Vallentuna, Sweden. She has made significant contributions to the field of pharmaceutical compositions, particularly in the treatment and prevention of oxalate-related disorders. Her innovative work focuses on addressing critical health issues associated with high plasma-oxalate levels and kidney function decline.

Latest Patents

Orla McCallion holds 1 patent for her invention titled "Compositions and methods for the treatment or prevention of oxalate-related disorders." This patent details pharmaceutical compositions and methods that utilize oxalate-degrading bacteria, which are particularly effective in treating late-stage hyperoxaluria. This condition is characterized by elevated plasma-oxalate levels and a progressive decrease in kidney function.

Career Highlights

Throughout her career, Orla has worked with various organizations, including Oxthera Intellectual Property and Oxthera Intellectual Property AB. Her work in these companies has been instrumental in advancing research and development in the field of oxalate-related disorders.

Collaborations

Orla has collaborated with esteemed colleagues such as Elisabeth Lindner and Maria Åkerman. These partnerships have contributed to her innovative research and the successful development of her patented compositions.

Conclusion

Orla McCallion's contributions to the treatment of oxalate-related disorders highlight her role as a pioneering inventor in the pharmaceutical field. Her work continues to impact the lives of those affected by these conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…